Advertisement
Product › Details
Perjeta™
Next higher product group | pertuzumab | |
Status | 2012-06-11 registration start | |
Organisation | Genentech (Group) | |
Group | Roche (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antibody cancer drug
- [1] StromaCare. (2/13/24). "Press Release: StromaCare Appoints Georges Rawadi as CEO". Lyon....
- [2] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
- [3] Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz....
- [4] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
- [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] SwiftPharma B.V.. (11/13/23). "Press Release: SwiftPharma and PlantForm Corporation Target Blockbuster Cancer Drug with New Contract Manufacturing Agreement for Plant-made Biosimilars". Ghent & Toronto, ON....
- [7] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....
- [8] Antiverse Ltd.. (10/16/23). "Press Release: Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics". Cardiff & Cambridge, MA....
- [9] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [10] Invios GmbH. (9/5/23). "Press Release: Invios Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding". Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top